GelStat Corporation Reports Consolidated Earnings Results for the Third Quarter Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter Ending December 31, 2014
The company increased revenue forecast to over $750,000 for the fourth quarter ending December 31, 2014. The increased revenue expectations are driven by continued strength in operations from recently acquired wholly owned subsidiary Mastix Medica and increasing sales of proprietary healthcare products.